Background

Background

The manufacturer of tadalafil (Lilly) was invited to submit evidence for this single technology appraisal in August 2012.

In September 2012, the manufacturer informed NICE that it would not be making an evidence submission for the appraisal of tadalafil for the treatment of benign prostatic hyperplasia. The manufacturer stated that there is insufficient evidence available to be able to undertake the appropriate analysis required to estimate the cost effectiveness of tadalafil within the defined treatment pathway outlined in Lower urinary tract symptoms: the management of lower urinary tract symptoms in men (NICE clinical guideline 97).

NICE has therefore terminated this single technology appraisal.

  • National Institute for Health and Care Excellence (NICE)